Metware Biotechnology Co., Ltd.
Metware Cloud Platform

Unraveling Cancer with Cutting-Edge Omics: MetwareBio at AACR 2024

Meet_MetwareBio_at_AACR2024_booth_4245_•_April_5-10,_2024__•__San_Diego,_CA,_USAThe American Association for Cancer Research (AACR) Annual Meeting 2024 is on the horizon! This premier event, taking place from April 5th to 10th at the San Diego Convention Center, brings together over 21,000 global cancer researchers for a week of exchanging and discussing groundbreaking cancer research. Metabolomics and multi-omics technologies are revolutionizing cancer research. At MetwareBio, a leading provider of these services, we're thrilled to participate in AACR 2024.

Harnessing the power of state-of-the-art mass spectrometry, refined workflows, and advanced bioinformatics analysis, we offer comprehensive proteomic, metabolomic, and multi-omics services. Our solutions cater to a wide range of projects, from unbiased general profiling to specific targted metabolomics or post-translational modification proteomics, for both small-scale investigations and large population studies. MetwareBio technical achievements have been presented and published in over 700 publications, including Cell, Nature Genetics, PNAS, Nature Communications, National Science Review, and many other international peer-reviewed journals. 

As an illustrative example, a recent publication in Gastroenterology titled 'Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress' identified ubiquitin-conjugating enzyme E2T (UBE2T) as a potential therapeutic target to combat gemcitabine resistance in pancreatic cancer and developed a promising gemcitabine sensitizer-pentagalloylglucose (PGG) in clinical translation setting. In this research, proteomics and metabolomics were combined to examine the effect of UBE2T on pyrimidine metabolism remodeling. The results showed that spontaneous PC mice with Ube2t deletion had a marked survival advantage after gemcitabine treatment, and UBE2T levels were positively correlated with gemcitabine resistance in clinical patients. Additionally, high-throughput compound library screening using organoids identified pentagalloylglucose (PGG) as a potent UBE2T inhibitor and gemcitabine sensitizer. The combination of gemcitabine and PGG diminished tumor growth in PDX models and prolonged long-term survival in spontaneous PC mice.

Mechanism of Gemcitabine and PGG Combination in PC

We are committed to providing you with professional, high-quality, and accurate services. We offer tailored solutions to meet your diverse research needs, unlocking thrilling insights in proteomics, metabolomics, lipidomics, and multi-omics joint analysis. Visit our booth #4245! Explore your projects and uncover the potential of omics for your cancer research.

Can't make it to AACR? Schedule a virtual meeting by emailing We look forward to connecting with you!


Leave us a message, and we will get you ASAP.